Abhilash P Appu1, Peethambaran Arun1, Jishnu K S Krishnan1, John R Moffett1, Aryan M A Namboodiri2. 1. Department of Anatomy, Physiology and Genetics and Neuroscience Program, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD 20814, USA. 2. Department of Anatomy, Physiology and Genetics and Neuroscience Program, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD 20814, USA. Electronic address: anamboodiri@usuhs.edu.
Abstract
BACKGROUND: The blood brain barrier (BBB) is critical for maintaining central nervous system (CNS) homeostasis by restricting entry of potentially toxic substances. However, the BBB is a major obstacle in the treatment of neurotoxicity and neurological disorders due to the restrictive nature of the barrier to many medications. Intranasal delivery of active enzymes to the brain has therapeutic potential for the treatment of numerous CNS enzyme deficiency disorders and CNS toxicity caused by chemical threat agents. NEW METHOD: The aim of this work is to provide a sensitive model system for analyzing the rapid delivery of active enzymes into various regions of the brain with therapeutic bioavailability. RESULTS: We tested intranasal delivery of chloramphenicol acetyltransferase (CAT), a relatively large (75kD) enzyme, in its active form into different regions of the brain. CAT was delivered intranasally to anaesthetized rats and enzyme activity was measured in different regions using a highly specific High Performance Thin Layer Chromatography (HP-TLC)-radiometry coupled assay. Active enzyme reached all examined areas of the brain within 15min (the earliest time point tested). In addition, the yield of enzyme activity in the brain was almost doubled in the brains of rats pre-treated with matrix metalloproteinase-9 (MMP-9). COMPARISON WITH EXISTING METHOD (S): Intranasal administration of active enzymes in conjunction with MMP-9 to the CNS is both rapid and effective. CONCLUSION: The present results suggest that intranasal enzyme therapy is a promising method for counteracting CNS chemical threat poisoning, as well as for treating CNS enzyme deficiency disorders. Published by Elsevier B.V.
BACKGROUND: The blood brain barrier (BBB) is critical for maintaining central nervous system (CNS) homeostasis by restricting entry of potentially toxic substances. However, the BBB is a major obstacle in the treatment of neurotoxicity and neurological disorders due to the restrictive nature of the barrier to many medications. Intranasal delivery of active enzymes to the brain has therapeutic potential for the treatment of numerous CNS enzyme deficiency disorders and CNS toxicity caused by chemical threat agents. NEW METHOD: The aim of this work is to provide a sensitive model system for analyzing the rapid delivery of active enzymes into various regions of the brain with therapeutic bioavailability. RESULTS: We tested intranasal delivery of chloramphenicol acetyltransferase (CAT), a relatively large (75kD) enzyme, in its active form into different regions of the brain. CAT was delivered intranasally to anaesthetized rats and enzyme activity was measured in different regions using a highly specific High Performance Thin Layer Chromatography (HP-TLC)-radiometry coupled assay. Active enzyme reached all examined areas of the brain within 15min (the earliest time point tested). In addition, the yield of enzyme activity in the brain was almost doubled in the brains of rats pre-treated with matrix metalloproteinase-9 (MMP-9). COMPARISON WITH EXISTING METHOD (S): Intranasal administration of active enzymes in conjunction with MMP-9 to the CNS is both rapid and effective. CONCLUSION: The present results suggest that intranasal enzyme therapy is a promising method for counteracting CNS chemical threat poisoning, as well as for treating CNS enzyme deficiency disorders. Published by Elsevier B.V.
Authors: R Benali; J M Tournier; M Chevillard; J M Zahm; J M Klossek; J Hinnrasky; D Gaillard; F X Maquart; E Puchelle Journal: Am J Physiol Date: 1993-02
Authors: Franz Worek; Thomas Seeger; Moshe Goldsmith; Yacov Ashani; Haim Leader; Joel S Sussman; Dan Tawfik; Horst Thiermann; Timo Wille Journal: Arch Toxicol Date: 2014-01-30 Impact factor: 5.153
Authors: Dongfen Yuan; Xiang Yi; Yuling Zhao; Chi-Duen Poon; Kristin M Bullock; Kim M Hansen; Therese S Salameh; Susan A Farr; William A Banks; Alexander V Kabanov Journal: J Control Release Date: 2017-03-24 Impact factor: 9.776
Authors: Michael C Veronesi; Mosa Alhamami; Shelby B Miedema; Yeonhee Yun; Miguel Ruiz-Cardozo; Michael W Vannier Journal: Am J Nucl Med Mol Imaging Date: 2020-02-25
Authors: Jishnu K S Krishnan; Peethambaran Arun; Bhadra Chembukave; Abhilash P Appu; Nivetha Vijayakumar; John R Moffett; Narayanan Puthillathu; Aryan M A Namboodiri Journal: J Neurosci Methods Date: 2017-05-10 Impact factor: 2.390